Epigenetic Reprogramming — Biological Age Reversal Without Identity Loss

Takahashi and Yamanaka (2006, Cell) induced pluripotent stem cells from mouse fibroblasts using Oct3/4, Sox2, Klf4 and c-Myc. That experiment established a route from differentiated cells to pluripotency; it did not measure an epigenetic ageing clock. Later in-vitro work by Olova et al. measured a decline in DNA-methylation age during human fibroblast reprogramming, reaching approximately zero by day 20 in that time course. Full pluripotency entails loss of the original somatic cell identity. The 2006 result supplies the reprogramming basis, and the later clock result supplies a distinct molecular-age observation; neither establishes reversal of biological age in a living organism while preserving cellular identity.

Ocampo et al. (Belmonte lab, Salk Institute, 2016, Cell) demonstrate that cyclic short-term induction of OSKM in a progeria mouse model (expressing a premature aging phenotype) extends lifespan by approximately 30% and reduces aging hallmarks without inducing tumours or loss of cellular identity. The key finding is that intermittent, limited OSKM expression reverses some epigenetic aging marks without completing dedifferentiation. The result is in a disease model (progeria) rather than normal aging, and in mice rather than humans. Lu et al. (Harvard, 2020, Nature) demonstrate partial reprogramming in retinal ganglion cells restores vision in aged mice with optic nerve damage, reducing epigenetic age of the cells and recovering visual function. Both results provide strong preclinical evidence for partial epigenetic reprogramming without identity loss. Both are in mice. Neither addresses the clinical translation question.

Altos Labs launched in January 2022 with $3 billion committed to research on cellular rejuvenation programming. Its launch materials identify Shinya Yamanaka as an unpaid senior scientific adviser overseeing research activities in Japan, not as chairman. This is evidence of substantial institutional commitment to studying the field, not evidence that partial reprogramming reverses biological age without identity loss. Funding amounts and investor identities for other companies are not needed to establish this bounded event.

Epigenetic-clock change requires careful interpretation. Kriukov et al. (2024) applied uncertainty-aware models to reprogramming datasets and found that some apparent rejuvenation signals depend on the clock and its prediction uncertainty. Separately, Borrus et al. (2024 preprint) compared intervention datasets across clocks and reported that some chronological-age-clock changes were sporadic and did not persist with more reliable clock versions or multiple-testing correction. Neither study establishes that caloric restriction or a named drug resets clocks without organismal benefit. Together they support the narrower measurement question in BN-001: clock movement alone has not validated durable, functional rejuvenation in a living organism.

Life Biosciences reported at the October 2024 AAO meeting that its locally delivered OSK therapy ER-100 improved retinal-function and axon-density measures in a non-human-primate model of optic-nerve injury. The reported experiment used a single intravitreal injection with daily systemic doxycycline. This is company-reported conference evidence in one disease model, not a peer-reviewed demonstration by multiple groups of reduced epigenetic age across primate blood and tissues. The announcement does not establish long-term safety, retained cellular identity across tissues, or organism-wide age reversal. It offers a limited preclinical bridge toward the later ER-100 clinical programme.

Life Biosciences, founded on Harvard researcher David Sinclair's partial-reprogramming work, receives Investigational New Drug (IND) clearance from the FDA for ER-100, a partial OSK (Oct4/Sox2/Klf4, omitting c-Myc) reprogramming therapy targeting optic neuropathies. The company states the trial — the first-ever human trial of a partial epigenetic reprogramming therapy — will begin in Q1 2026. The preclinical pathway cited (rodent optic-nerve-injury recovery, followed by non-human-primate work) extends directly from the IN-002 and IN-005 evidence already in this record. This is the precise development AT-001 names as the resolution attractor: "first human safety data" at partial-reprogramming doses. The trial has not yet reported results as of this assessment — IND clearance and trial initiation are regulatory and operational milestones, not efficacy or safety data — so the human clinical evidence gap that AS-001 identified as complete is now closing rather than closed. The claim's central uncertainty (does partial reprogramming work, safely, in humans) remains unanswered, but for the first time it is being asked directly rather than only by extrapolation from animal models.

Life Biosciences reports that the first participant was dosed on June 9, 2026 in the Phase 1 ER-100 trial for open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. ClinicalTrials.gov lists NCT07290244 as a recruiting first-in-human Phase 1 study sponsored by Life Biosciences. This converts the prior IND-clearance milestone into actual human exposure to partial OSK epigenetic reprogramming. It is materially closer to AT-001, but no trial results have been posted: dosing establishes operation of the clinical test, not safety, efficacy, biological-age reversal, identity preservation, or validated functional rejuvenation. The central evidentiary boundary therefore remains unresolved.